Assorted news from the last week:
In a new study led by Yale Cancer Center researchers, neuromuscular dysfunction is found to be prevalent in long-term childhood cancer survivors, continues to increase post-therapy, and is associated with adverse health and socioeconomic outcomes. The findings were published in the journal Cancer, Epidemiology, Biomarkers & Prevention.
Research suggests that children with average risk medulloblastoma can receive radiation to a smaller volume of the brain at the end of a six-week course of treatment and still maintain the same disease control as those receiving radiation to a larger area. But the dose of preventive radiation treatments given to the whole brain and spine over the six-week regimen cannot be reduced without reducing survival.
Upcoming Webinars and Online Opportunities:
Join us for the 2021 CAC2 Annual Summit, a robust virtual meeting to unite CAC2 members and guests to advance our work for the childhood cancer community: Thursday, June 24th noon – 5:00 pm ET and Friday, June 25th noon – 4:00 pm EDT. Register here. Read more about the Summit here.
ACCELERATE will host the 2nd episode of their webinar series Orphan Drug Regulations on June 29 at 11:00 EDT. It will include topics such as
- How does the orphan medicines regulation work in EU, US and Japan?
- How did it impact the field of rare diseases? What are the issues now in Research & Development?
- The oncology paradox: Why did the current adult-based approach not work for childhood cancers? How can we improve the situation to better target the ‘young patients’ needs?
Both in-person and virtual CureFest registration is now open! Make your plans for September 25-26.
- CAC2 Childhood Cancer Community News Digest (May 2-8)
- Guest Blog–National Cancer Institute Launches the CCDI Childhood Cancer Data Catalog
- CAC2 Childhood Cancer Community News Digest (April 25-May 1)
- CAC2 News–Great.com Interviews Coalition Against Childhood Cancer About A Future Without Childhood Cancers
- Community News–Congress Introduces the Childhood Cancer STAR Reauthorization Act